Evidence map›Paper›PMID 34257800›Full record

ArticleOxidative medicine and cellular longevity2021

Deficiency of Antioxidative Paraoxonase 2 (Pon2) Leads to Increased Number of Phenotypic LT-HSCs and Disturbed Erythropoiesis.

Lisa Spiecker, Ines Witte, Julia Mehlig, Viral Shah, Markus Meyerhöfer, Patricia S Haehnel, Victoria Petermann, Andrea Schüler, Piyush More, Nina Cabezas-Wallscheid and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. The Paraoxonase (International journal of molecular sciences · 2025
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Lisa SpieckerDepartment of Pharmacology, Johannes Gutenberg University Medical Center, Mainz, Germany.ORCID https://orcid.org/0000-0003-1801-4630
Ines WitteDepartment of Pharmacology, Johannes Gutenberg University Medical Center, Mainz, Germany.ORCID https://orcid.org/0000-0001-8868-7051
Julia MehligDepartment of Pharmacology, Johannes Gutenberg University Medical Center, Mainz, Germany.ORCID https://orcid.org/0000-0002-1282-6243
Viral ShahDepartment of Hematology, Medical Oncology and Pneumology, University Medical Center, Mainz, Germany.ORCID https://orcid.org/0000-0003-1334-8121
Markus MeyerhöferDepartment of Hematology, Medical Oncology and Pneumology, University Medical Center, Mainz, Germany.
Patricia S HaehnelDepartment of Hematology, Medical Oncology and Pneumology, University Medical Center, Mainz, Germany.ORCID https://orcid.org/0000-0003-3007-8856
Victoria PetermannDepartment of Pharmacology, Johannes Gutenberg University Medical Center, Mainz, Germany.ORCID https://orcid.org/0000-0003-2016-5657
Andrea SchülerDepartment of Hematology, Medical Oncology and Pneumology, University Medical Center, Mainz, Germany.
Piyush MoreDepartment of Pharmacology, Johannes Gutenberg University Medical Center, Mainz, Germany.ORCID https://orcid.org/0000-0002-6232-6124
Nina Cabezas-WallscheidMax Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany.ORCID https://orcid.org/0000-0003-0870-0530
Sven HorkeDepartment of Pharmacology, Johannes Gutenberg University Medical Center, Mainz, Germany.ORCID https://orcid.org/0000-0003-1309-3923
Andrea PautzDepartment of Pharmacology, Johannes Gutenberg University Medical Center, Mainz, Germany.ORCID https://orcid.org/0000-0003-3969-0056
Andreas DaiberDepartment of Cardiology, Cardiology I, Johannes Gutenberg University Medical Center Mainz, Germany.ORCID https://orcid.org/0000-0002-2769-0094
Daniel SascaDepartment of Hematology, Medical Oncology and Pneumology, University Medical Center, Mainz, Germany.ORCID https://orcid.org/0000-0003-0330-7959
Thomas KindlerDepartment of Hematology, Medical Oncology and Pneumology, University Medical Center, Mainz, Germany.ORCID https://orcid.org/0000-0002-0383-0507
Hartmut KleinertDepartment of Pharmacology, Johannes Gutenberg University Medical Center, Mainz, Germany.ORCID https://orcid.org/0000-0003-2202-3548
Johannes Gutenberg University Mainz · DEMax Planck Institute of Immunobiology and Epigenetics · DE

Funding

Cancer Control Education ProgramT32CA057726 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa B Gilkey, Melissa A. Troester · 2017 to 2026
$3.7M
NCI NIH HHS T32 CA057726
6 · The paper itself

Abstract

backgroundLong-term hematopoietic stem cells (LT-HSCs) reside in bone marrow niches with tightly controlled reactive oxygen species (ROS) levels. ROS increase results into LT-HSC differentiation and stem cell exhaustion. Paraoxonase 2 (PON2) has been shown to be important for ROS control.

objectivesWe investigate the effects of inactivation of the METHODS AND

resultsIn young mice with inactivated

conclusionsIn summary, our current data indicate that PON2 is involved in the regulation of HSC functions.

Indexed as

AnimalsAntioxidantsAryldialkylphosphataseCell DifferentiationCell LineErythropoiesisHematopoietic Stem CellsMicePhenotypeReactive Oxygen SpeciesAntioxidantsAryldialkylphosphatasePON2 protein, mouseReactive Oxygen Species

Identifiers

PMID34257800
PMCPMC8253644
OpenAlexW3175789530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.